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Abstract
Background and aims Cachexia is a syndrome characterized by marked involuntary loss of body weight. Recently, adipose
tissue (AT) wasting has been shown to occur before the appearance of other classical cachexia markers. We investigated
the composition and rearrangement of the extracellular matrix, adipocyte morphology and inflammation in the subcutaneous
AT (scAT) pad of gastrointestinal cancer patients.
Methods Surgical biopsies for scATwere obtained from gastrointestinal cancer patients, who were signed up into the following
groups: cancer cachexia (CC, n = 11), weight-stable cancer (WSC, n= 9) and weight-stable control (non-cancer) (control, n= 7). The
stable weight groups were considered as those with no important weight change during the last year and bodymass index<25kg/m2.
Subcutaneous AT fibrosis was quantified and characterized by quantitative PCR, histological analysis and immunohistochemistry.
Results The degree of fibrosis and the distribution and collagen types (I and III) were different in WSC and CC patients. CC
patients showed more pronounced fibrosis in comparison with WSC. Infiltrating macrophages surrounding adipocytes and CD3
Ly were found in the fibrotic areas of scAT. Subcutaneous AT fibrotic areas demonstrated increased monocyte chemotactic
protein 1 (MCP-1) and Cluster of Differentiation (CD)68 gene expression in cancer patients.
Conclusions Our data indicate architectural modification consisting of fibrosis and inflammatory cell infiltration in scAT as
induced by cachexia in gastrointestinal cancer patients. The latter was characterized by the presence of macrophages and
lymphocytes, more evident in the fibrotic areas. In addition, increased MCP-1 and CD68 gene expression in scAT from cancer
patients may indicate an important role of these markers in the early phases of cancer.
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Introduction
Cachexia is a wasting condition, directly associated with 22–40%
of all cancer deaths.1,2 It has been defined as ‘a multifactor
syndrome’, characterized by ongoing loss of skeletal muscle
mass (with or without loss of fat mass) that cannot be fully
reversed by conventional nutritional support and leads to
progressive functional impairment.3,4 Although muscle wasting
has been the main focus of cachexia-related research,5,6 studies
show that fat loss occurs more rapidly and more precociously
than the reduction of lean mass in cancer cachexia (CC)7–9 and
may extend up to 80% within a very short interval, especially
in the immediate period preceding death. Still, more recently,
we have shown that the adipose tissue (AT) of cachectic cancer
patients, in particular the subcutaneous AT (scAT) depot, is a
possible relevant systemic source of inflammatory molecules
during the development of the disease.10
Several factors have been demonstrated to contribute to
cachexia-related loss of AT, such as (i) increased lipid mobiliza-
tion due to enhanced adipocyte triglyceride lipolysis,8,11 (ii) re-
duced lipogenesis and fatty acid esterification due to decrease
of both fatty acid synthase and lipoprotein lipase activity12 and
(iii) impairment of fat cell turnover (pre-adipocyte/mature
adipocyte), resulting in a disruption in the organization and
OR IG INAL ART ICLE
© 2015 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle (2015)
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12037
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
development of AT.13 In addition to that, several morphological
and molecular changes in AT depots of rats during the progres-
sion course of CC have been described.9,14–16 Most of the alter-
ations, nevertheless, are perceived before any detectable
morphological disruption, notably the down-regulation of
genes related with adipogenesis, metabolism and mature adi-
pocyte function. Furthermore, AT inflammation is a well-
characterized aspect of the syndrome.9,17,18 Such condition
seems to be most apparent at the final stages of cachexia
(cachexia to refractory cachexia).
AT has been described as a heterogeneous tissue that
possesses marked anatomically-related depot specialization in
regard to many parameters, including cellularity, form of
growth and expansion, metabolism, production of and
response to cytokines, hormones, density and distribution of
innervation, as well as to fatty acid composition (reviewed by
Pond19). Several chronic diseases, such as obesity,20 metabolic
syndrome and lipodystrophy,21 induce AT remodelling, involv-
ing two major processes: adipose cell morphometric changes
(hypertrophy or atrophy) and immune cells accumulation.
Inflammation, endoplasmatic reticulum stress and hypoxia
are also part of the general biologic alterations subsidizing
the attraction and retention of inflammatory cells in AT.22 AT
extracellular matrix (ECM) remodelling has been found to play
an essential role in adipogenesis22 and tissue structure estab-
lishment.23 In obesity, these alterations were demonstrated
to be crucial to accommodate cellular alterations.24 In db/db
obese mice, epididymal AT morphological changes occur con-
comitantly to up-regulation of various types of collagens, such
as I, IV and VI.25 The former is related with increased adipocyte
size.26 This feature is generally followed by persistent inflam-
matory stimulus in AT that may underline excessive synthesis
of ECM components. Consequently, subsequent interstitial
deposition of fibrotic material (fibrosis) and enhanced expres-
sion of ECM proteins seem to be a result of a pervasive tissue
response to unresolved chronic inflammation.20 Divoux
et al.20 have reported increases in ECM components secretion
induced by products synthesized by macrophages infiltrated in
the AT (ATMϕs), suggesting a possible interaction between
inflammatory cells and AT remodelling. In the same study,
other inflammatory cells, including T-lymphocytes and mast
cells, were shown to participate in one such process. However,
despite AT remodelling being well described in obesity, few
studies have addressed this topic in CC.
Thus, to obtain broader insight into AT remodelling in the
setting of CC, we have analysed the scAT depot of cancer
patients. The choice of scAT, rather than visceral AT, relies
on the fact that we have previously shown10 that this pad
responds more precociously to the presence of the tumour
in the organism, acting as a source of inflammatory markers.
Additionally, it is an ideal tissue for the obtainment of
biopsies.
Firstly, we evaluated fibrosis in a qualitative and quantita-
tive manner and in particular, collagen density in scAT of
weight-stable and cachectic cancer patients. Secondly, we
characterized the inflammatory cells surrounding fibrotic
depots. Finally, we determined scAT inflammatory gene ex-
pression in cancer patients. The analysis shows discrete early
morphological modifications in scAT, followed by increased
inflammatory cell infiltration and fibrosis, which are more
evident in the cachectic cancer patients.
Materials and methods
Patients and sample collection
Patients were recruited between November 2008 and July
2010 at University Hospital of the University of São Paulo
(n = 26). The inclusion criteria were as follows: 1, not having
received prior anticancer treatment and 2, willingness to par-
ticipate. The exclusion criteria were as follows: chemotherapy
at the time of the study; continuous anti-inflammatory ther-
apy; and kidney or liver failure, acquired immunodeficiency
syndrome, inflammatory bowel disease or chronic inflamma-
tory processes not related with cachexia, such as autoim-
mune disorders. Patients with body mass index (BMI)
greater than 29.9 were also excluded from the study. The
study was approved by the Ethics Committee from the
Institute of Biomedical Sciences and by the Human Ethics
Committee of the University of São Paulo Hospital (CEP-ICB/
USP 1117/13, CEP-HU/USP 752/07 and 1117/13, CAAE
0031.0.198.019-07). The investigation was explained in detail
to each patient, and written informed consent was obtained.
They were separated into three groups, based on diagnosis
after surgery. The subjects were subdivided into CC (CC,
n = 12) and weight-stable cancer (WSC, n = 7) and weight-
stable control (non-cancer) (control, n = 7). Patients were con-
sidered cachectic based on criteria from the international
consensus.2 Cachexia is recognized in patients with weight
loss >5% in the past 6months or any degree of weight loss
>2% in the last 6months + BMI <20 kg/m2. The stable weight
groups were considered as those with no important weight
change during the previous year and BMI <25 kg/m2. In the
cancer groups (CC and WSC), the tumour primary location
was colon (n = 8), stomach (n = 5), pancreas (n = 2) and other
(n = 4). The control group included patients undergoing sur-
gery for incisional hernia (n = 5) and chronic cholecystitis
(n = 2). The study was designed as ‘intention to compare’;
therefore, all subjects were kept in the analyses despite a
few missing values of the measurements. Table 1 presents
the general characteristics of patients in each group.
Clinical parameters assessment
Height and weight were determined, and approximately
10mL of blood was collected after overnight fast, within the
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venous access procedure for anaesthesia during the surgery,
allowing the measurement of plasma C-reactive protein, se-
rum urea, creatinine and haemoglobin. Plasma and serum
samples were then immediately frozen at 80°C, until
further analysis. Tumour staging was determined post-
operatively, according to the guidelines of the Union for
International Cancer Control TNM.27
Adipose tissue biopsies
Approximately 1 g of subcutaneous white AT (by approximate
anatomical site) was collected in within a 5min interval,
similarly to that described by Agustsson et al.11 A portion of
AT biopsy was immediately transferred into liquid nitrogen
and kept at 80 °C before RNA analysis. The other part was
fixed overnight at 4 °C in 4% paraformaldehyde and proc-
essed for standard paraffin embedding.10 This procedure pre-
sents a minimal degree of risk and does not interfere with the
standard surgery procedure.
Morphological analysis
The sequential 5μm sections obtained were first stained
with haematoxylin and eosin and then, with picro sirius
red. The sections were analysed with a Leica microscope
(DM 750), equipped with filters to provide circularly polar-
ized light. For the analysis of morphometric aspects, the
area, average diameter, perimeter and shape were
measured by Imagen Pro-Plus 6.0 (100 adipocytes per
stained section). Picro sirius red staining sections allowed
collagen fibres detection with different colours.28 Type I col-
lagen fibres appear orange to red, whereas the thinner type
III collagen fibres are stained with a yellow to green hue.
Tissue images were obtained with a ×40 objective lens, re-
corded on a digital camera (DFC 295, Leica), displayed on
a high-resolution monitor (LG, Flatron, E1941) and analysed
with SigmaScan Pro image analysis (Chicago, IL, USA). For
the different morphological analysis, different histological
slices (non serial sections) from the same group were
employed.
Immunohistochemistry
Immunohistochemistry of AT was carried out with sections
fixed in buffered formalin and embedded in paraffin. Depara-
ffinized sections (5μm) were stained with haematoxylin and
eosin. After quenching of endogenous peroxidase activity
with 0.3% H2O2 in methanol and blocking of free protein-
binding sites with 5% normal goat serum, sections were im-
munostained for immune cells: macrophages with CD68
anti-mouse KP-1 monoclonal antibody (DAKO, Denmark—
Ref m 0814), neutrophils with CD15 (DAKO, Denmark—Ref
IR062) and T lymphocytes with CD3 (Cell Marque, Rocklin—
Ref 103A-76) antibodies. Specific secondary antibodies were
peroxidase (horseradish peroxidase) conjugated. Histochemi-
cal reactions were performed employing Vecta stain ABC Kit
Table 1 Characteristics of study groups
Measure Control WSC CC P
n 7 7 12
Gender (male/female) 3–4 3–4 8–4
Age (years) 59.0± 12.7 68.2±13.3 61.5±16.9 0.722
Weight (kg) 59.9± 8.5 63.4±10.6 69.5±9.2 0.105
Height (m) 1.62±0.04 1.56±0.07 1.63±0.06 0.053
BMI (kg/m2) 21.9± 1.2 24.2±1.7 21.1±3.6 0.073
Weight loss (kg) 1.4± 1.8 2.7±0.7 13.6±4.1 <0.01
Weight loss (%) 2.8± 0.3 4.3±0.7 19.9±6.6 <0.01
Tumour stage
IA–B 1 (14%) 1 (8%)
IIA–B 3 (43%) 3 (25%)
IIIA–B 2 (29%) 5 (42%)
IV 1 (14%) 3 (25%)
S-Hg (g/dL) 12.6± 1.2 10.8±1.9 11.4±1.8 0.147
P-urea (mg/dL) 35.2± 11 34.3±14 30.2±15 0.622
P-creatinine (mg/dL) 0.88±0.2 0.90±0.3 0.84±0.3 0.892
S-TAG (mg/dL) 148±19 133±15 101±13 <0.01
S-cholesterol (mg/dL) 205±14 203±16 173±18 <0.01
S-LDL (mg/dL) 105±12 102±13 83±15 <0.01
P-IL-6 (pg/mL) 9.2± 8.2 36.6±20 96.4±99 0.034
P-CRP (pg/mL) 2.1± 2.2 4.4±3.5 28.2±20 <0.01
BMI, body mass index; CC, cancer cachexia; CRP, C-reactive protein; Hg, haemoglobin; IL, interleukin; LDL, low-density lipoprotein levels;
n, number of patients; P, plasma; S, serum; TAG, triglyceride serum levels; WSC, weight-stable cancer.
Values are mean± standard deviation.
Statistical analysis, P vs. control subjects.
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(Vector Laboratories) and Sigma Fast 3,3-diaminobenzidine as
substrate (Sigma, St. Louis, MO). Sections were counter-
stained with haematoxylin.
Gene expression analysis
Total RNA of the samples was isolated with TriPure Isolation
Reagent (Roche®), following the recommendations of manu-
facturer,29 and total RNA concentration, quantified by spec-
trophotometry (Nanodrop ND-1000). Complementary DNA
synthesis was carried out employing 13μL assay mix contain-
ing 3μg total RNA, 10U RNAse inhibitor, 2μL random primers,
2μL dNTP (10 nmol), 2μL dithiothreitol, 10U Moloney Murine
Leukemia Virus (M-MLV) reverse transcriptase and 4μL of ×10
reaction buffer (100mM Tris-HCl, 500mM KCl; 150 nM MgCl2
in nuclear free water) (Invitrogen). Gene expression of CD68
(NM_001040059.1, forward 5’ACT GAA CCC CAA CAA AAC
CA3’, reverse 5’TTG TAC TCC ACC GCC ATG TA) and MCP-1
(CCL2) (NM_002982.3, forward 5’ CCC CAG TCA CCT GCT
GTT AT 3’ and reverse 5’TGG AAT CCT GAA CCC ACT TC 3’).
Five microlitres of cDNA (25 ng) were mixed with 2x SYBR
Green PCR master mix (Applied Biosystems) and primers
(Invitrogen). Quantitative real-time PCR was performed with
an ABI 7300 real-time systems (Applied Biosystems). The
mRNA levels were determined by comparative Ct method
for each sample. A ΔCt value was obtained by subtracting
18 S values from those of the gene of interest. The average
ΔCt value of the control group was then subtracted from the
sample to derive a ΔΔCt value. The expression of each gene
was evaluated by 2(ΔΔCt).
Statistical analysis
The statistical analysis was performed with the commercially
available statistical package from SigmaStat (version 3.1,
Sigma Stat, SYSTAT, Point Richmond, CA). Data are expressed
as mean ± standard error and analysed by one-way analysis of
variance. When a significant F-value was found by one-way
analysis of variance, a Bonferroni’s post hoc test was
performed to demonstrate all pairwise multiple comparisons
between the means. All calculated P-values were two sided,
and a P< 0.05 was considered significant.
Results
Clinical findings
Baseline characteristics of the patients are shown in Table 1.
The subjects in the three groups were of similar age and BMI.
The body mass 6–12months before inclusion in the study, as
reported by patients, showed difference among the groups.
CC mass was significantly lower, as compared with WSC and
control, considering weight loss, both as absolute values
(13.6 kg, P< 0.01, compared with control) as relative values
(19.9%, P< 0.01, compared with control). Plasma lipid profile
was affected by CC, with decreased level of triglyceride se-
rum levels (31.8%, P< 0.01), total cholesterol (15.6%,
P< 0.01) and low-density lipoprotein levels (14.3%,
P< 0.01) when compared with the control patients. There
was no difference with respect to other biochemical parameters
(i.e. plasma creatinine and urea and serum haemoglobin values).
We did not evaluate lean body mass, although groups
were matched by BMI. CC patients showed values ranging
from 8.9% to 30.8% of body weight loss during the previous
6months and C-reactive protein higher than 5μg/mL, as
well as increased levels of interleukin (IL)-6 (12.6-fold and
9.4-fold, respectively, P< 0.001) compared with control, in-
dicating that the studied cachectic patients demonstrated
weight loss and increased plasma inflammatory markers.
WSC patients showed values ranging from 3.2% to 5.4% of
body weight loss during the previous 6months and
C-reactive protein values ranging from 1.2 to 10.7 5μg/mL.
However, there was no statistical difference when compared
with the control group.
Morphological analysis and collagen diversity in
scAT
Cancer cachexia patients showed body weight loss and BMI
reduction, suggesting the possibility that modification of AT
cell morphology may be a response to CC. In order to address
this question, we determined cell perimeter and the cross-
sectional area in samples of the subcutaneous depot
(Figure 1). Light microscopy examination indicates that mor-
phometric alteration of scAT is only evident in the CC group
(Figure 1A–C). In scAT from CC, adipocyte size, determined
as sectional area (Figure 1D), and cell perimeter (Figure 1E)
showed a decrease of 32.9% (P< 0.05) and 18.5% (P< 0.05),
respectively, compared with the control samples.
When examined under polarized light microscopy, the
same samples from CC patients demonstrated that types I
(red label) and III (green label) collagen fibres were present
around the adipocytes, in organized bundles of various thick-
nesses (Figure 2A–F). As compared with control patients, CC
samples showed an increase of 1.7-fold (P< 0.01) of total
type I collagen, no changes in type III collagen (P = 0.10) and
an increase in collagen I–III ratio (P = 0.0159) (Figure 2G–H).
Inflammatory profile and cell infiltration
Taking into account the scope of data regarding AT remodel-
ling induced by cachexia, notably the modification in total
collagen density (fibrosis), we also examined the presence
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of inflammation and infiltrated cells in scAT from the patients.
Immunostaining for macrophages (CD68), T-lymphocytes
(CD3) and neutrophils (CD15) and analysis of gene expression
of MCP-1 and CD68 were carried out (Figures 3–5).
Although the presence of CD15 neutrophils was minimal in
CC, we observed an abundant number of macrophages
stained with CD68 surface markers in the groups (CC and
WSC) (Figure 3). Additionally, in tissue sections stained for
CD68 positive cells, we found higher intensity that was more
pronounced in the surrounding of adipocytes [crown-like
structures (CLS)] in CC (Figure 4A, C). However, crown aggre-
gates were not extensive, and there was no signal of syncytial
giant cells. Less frequently, sections for CD3 positive cells
showed irregular distribution more often observed in the
scAT fibrotic areas from CC (Figure 4B, D).
CD68 mRNA expression increased in scAT obtained
from CC patients (109-fold, P = 0.029, respectively), when
compared with the control group (control vs. CC). In scAT of
WSC, an increase of 48-fold in MCP-1 mRNA levels was
detected, when compared with the control group (P = 0.010)
(Figure 5).
Discussion
The present study documents, for the first time, increased
number of ATMϕs in scAT obtained from gastrointestinal
cachectic cancer patients. One such change was accompanied
by ECM remodelling and associated with adipocyte size
reduction and AT atrophy. Fibrosis was detected, as well as
the presence of distinct patterns of fibrous material
surrounding adipocytes, while collagen fibre organization
was altered in scAT samples obtained from cancer patients.
Figure 1 Morphological characteristics of subcutaneous adipose tissue depot in cachexia and control patients. Haematoxylin and eosin stained sec-
tions of subcutaneous tissue from (A) weight-stable subjects and control, (B) weight-stable cancer (WSC) patients and (C) cancer cachexia (CC) pa-
tients. Morphometric analysis of sectional area (D) and (E) perimeter of adipocytes from different experimental groups. Photomicrographs (A–C)
illustrate the most representative images considering data related to morphological analysis (D, E). Values are mean ± SEM. * P< 0.05 vs. control
subjects.
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In this aspect, markedly increased total collagen amounts
were found in the cachectic patients while being already
mildly increased in the cancer (weight stable) patients. Inter-
estingly, such structural modification of scAT was accompa-
nied by increased inflammatory cells subset presence,
which was more conspicuous in the cachectic patients.
CD68-labelled ATMϕs localized to crowns surrounding adipo-
cytes and expressed higher mRNA levels of scavenger recep-
tor (CD68), as well as chemokine attractant for macrophages
(MCP-1). Additionally, CD3 Ly was more abundant in the
fibrotic areas in scAT samples from cachectic patients, in a
different fashion compared with infiltrated ATMϕs.
The hallmark of CC is body weight loss.30,31 Loss of muscle
and AT mass, anorexia, anaemia and alterations in metabo-
lism are also evident during the development of the disease.
In particular, AT catabolism followed by tissue mass depletion
(atrophy) and metabolic dysregulation are consistent and
prominent findings in CC patients.1,9,10,31,32 In this aspect,
the present study shows adipocyte size reduction in scAT of
cachectic cancer patients. This aspect was not evident in
the WSC patients. AT atrophy induced by cachexia has been
consistently demonstrated in both patients7,33 and animal
models.9,34 In CC, longitudinal investigation has suggested
that fat loss is not only due to loss of adipocyte volume
(lipolysis)29,34,35 but also may be attributed to a decrease in
lipid accretion in these cells,36 both resulting in a smaller
cell.37 Recently, a well-designed investigation8 showed con-
sistent evidence that lipases in AT breakdown stored fat,
contributing to cancer-associated cachexia. However, despite
several studies having consistently shown AT atrophy as a re-
sult of cachexia, the associated mechanisms are still not fully
elucidated.
Another aspect addressed was ECM fibrosis, in order to as-
sess whether there was AT remodelling in this scenario. CC
patients showed ECM increased fibrosis in AT, with evident
collagen-fibril staining. Simultaneously, an increase in both
types I and III collagen content was observed in these pa-
tients, whereas in WSC, only a discrete change detected in
type I collagen was found. A recent microarray data analysis
from scAT of cachectic patients demonstrated a possible con-
nection between regulation of energy turnover, cytoskeleton
and ECM, with loss of AT.38 In an animal model of cachexia,
AT fibrosis was demonstrated by ultrastructural analysis
showing severe delipidation and alterations in cell membrane
conformation, irregular cytoplasmic projections and increased
electron-dense mitochondria. An enhanced level of collagen-
fibril staining was also evident in the tumour-bearing group.39
In fact, the ECM is one of the most important regulators of
cellular and tissue function in the body.40 Disruption in ECM
leads to marked metabolic dysregulation and failure to
Figure 2 Picro sirius red staining sections of subcutaneous adipose tissue in cachexia and control patients. Collagen fibres are presented in different
colours. Type I collagen fibres are orange to red, whereas the thinner type III collagen fibres appear yellow to green from (A, B) weight-stable sub-
jects and control, (C, D) weight-stable cancer (WSC) patients and (E, F) cancer cachexia (CC) patients. Total collagen quantification in cachexia and
control patients of (G) type I collagen and (H) types I–III ratio. Values are mean ± SEM. * P< 0.05 vs. control subjects.
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expand AT in both obese patients and experimental obesity
(high fat diet and ob/ob knockout).41 In the same way, AT re-
duction as induced by a body weight reduction programme
was shown to result from modified ECM gene expression pro-
file.42 In obese patients, body fat loss as a consequence of
gastric bypass was associated with increased fibrosis in fat de-
pots after a 3month to 1 year post-surgery period.43 How-
ever, even considering the important role of ECM to AT
homeostasis, there is limited information regarding quantita-
tive EMC analysis in cachectic cancer patients. The few stud-
ies that have addressed this question propose that AT solely
adjusts its extracellular environment to adapt to the shrinking
volume of the fat cells.11,38 Contrary to this view, we show a
robust increase in total collagen content and additionally,
that, even before any morphofunctional disruption in AT
occurs, as reported for WSC patients, AT is already affected
by the syndrome. Indeed, it seems that the process of AT
remodelling induced by cachexia is triggered before any of
the clinical signs of the disease. Additional studies should
take place to fully confirm this hypothesis.
As described above, several researchers have shown that
AT ECM remodelling is a crucial event to accommodate
obesity-induced cellular alterations. One such process has
also been described to be the end point of a persisting in-
flammatory stimulus (unresolved chronic inflammation) in
AT, which may be responsible for the excessive synthesis of
ECM components and subsequent interstitial deposition of
fibrotic material.44,45 There are, however, no studies, to our
knowledge, that describe the nature of the inflammatory
infiltrate in the AT of cachectic patients.
One previous study by our group demonstrated that AT, in
particular, scAT, contributes in a significant manner to
systemic inflammation, as a potent source of inflammatory
factors.10 We presently show an accentuated modification
in gene expression, as well as in plasma concentration of
adipokines and pro-inflammatory molecules in cachectic
gastrointestinal cancer patients, in relation to their non-
cachectic counterparts. These include adiponectin, leptin,
tumour necrosis factor-α, IL-6 and IL-10. Furthermore, in
the present study, we provide new information in regard to
the inflammatory cells found in the AT of CC patients. Tissue
sections stained for CD68 ATMϕs positive cells show a higher
intensity for the macrophage marker, especially in the
surrounding surface of adipocytes (CLS) in CC. However,
crown aggregates were not as cell dense as those normally
described in obesity, and there was no signal of occasional
Figure 3 Identification of different immune cell types present in subcutaneous adipose tissue obtained from cancer cachexia patients. Serial
sections of weight-stable subjects and control, weight-stable cancer (WSC) patients and cancer cachexia (CC) patients were stained with markers
of macrophages (CD68), T-lymphocytes (CD3) and for neutrophils (CD15). Nuclei were stained with haematoxylin (blue staining). HE, haematoxylin
and eosin staining.
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coalescence to form syncytial giant cells. In a different way,
CD3 Ly positive cells were the main immune cells found in
the fibrotic areas. We previously hypothesized that infiltrat-
ing ATMϕs may play an important role(s) in cachexia-
associated AT remodelling, based on our observation that
ATMϕs in cachectic rats and humans are placed surrounding
or in close proximity to the adipocytes.46 In addition, we
demonstrated that ATMϕs aggregates display a CLS pattern.
This may be a consequence of an increased lipid scavenging
function of ATMϕs, induced by CC. In obesity, a positive rela-
tionship between infiltrating ATMϕs and AT remodelling has
been demonstrated.41,47–49 In particular, CLS are described
at sites of adipocyte death. Such structures are related with
envelopes and ingest the moribund adipocyte and its
Figure 4 Immunohistochemistry for immune cells from weight-stable subjects and control, weight-stable cancer (WSC) patients and cancer
cachexia (CC) patients. Subcutaneous adipose tissue (scAT) macrophages localize to crown-like structures (CLS) around individual adipocytes, which
increase in frequency with cancer cachexia. Light microscopy of scAT of CC patients showing CD68 immunoreactive macrophages (brown colour)
aggregated to numerous (C, CC patients) CLS among unilocular adipocytes. Note that almost all CD68 immunoreactive macrophages are organized
to form CLS. CD3 immunoreactive T-lymphocyte shows positive cells in fibrotic areas, stained with DAB (brown colour) (arrow). Nuclei were stained
with haematoxylin (blue labelling). Bar (μm): 50 μm for A and B; 25 μm for C and D.
Figure 5 Expression levels of genes involved in the inflammation of subcutaneous adipose tissue depots in subjects from different experimental
groups. Real-time PCR analysis of RNA isolated from weight-stable subjects and control, weight-stable cancer (WSC) patients and cancer
cachexia (CC) patients. mRNA levels of target genes were normalized to 18 S. Values are mean ± SEM for five to nine samples per group. * P< 0.05 vs.
control subjects.
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potentially cytotoxic remnant lipid droplet.47 Consequently,
CLS become lipid-laden ‘foam cells’47 frequently observed in
AT in obesity. In an animal model of cachexia, we have
shown46 that foam-cell resembling macrophages are present
in the AT. During CC, increased lipolysis has been consistently
demonstrated in both patients7,11 and animal models9,32 and
that might be an important source of lipids to ATMϕs. In
tumour-bearing animals, lipid profile was modulated by the
cachectic state in an anatomical region-related pattern.
Visceral AT composition is changed and presents increased
storage of monounsaturated fatty acids (16:1), as well as
decreased percentage of stearic acid, a saturated fatty acid.50
In the same animal model, abundant lipid inclusions were
found in infiltrated ATMϕs in the mesenteric depots obtained
from cachectic rats. Those cells also exhibited increased
tumour necrosis factor-α secretion when stimulated with li-
popolysaccharide.45 However, this aspect was not assessed
in the present study.
Infiltrating inflammatory cells secrete pro-inflammatory
mediators that are enhanced in the scAT of CC patients.10
Up-regulation of IL-6 has been a consistent finding in several
studies, notably in cachectic patients, independent of the
aetiology of the syndrome.51 We previously demonstrated
that plasma IL-6 is markedly increased during cachexia, a re-
sult that may represent an interesting tool for diagnostic pur-
poses. Although our previous study reported increased
inflammatory cytokine profile gene expression in scAT sam-
ples from CC patients, we herein show that CD68 gene ex-
pression was also increased in scAT from these patients,
corroborating the observation that CD68 ATMϕs positive
cells were more abundant in the same situation. Interestingly,
MCP-1 gene expression was solely augmented in WSC sam-
ples, with no changes in CC patients. ATMϕs infiltrate to AT
as circulating monocytes in response to AT secretion of
MCP-1, which recruits monocytes expressing the C-C chemo-
kine receptor type 2. This is one of the initial steps to trigger
inflammatory response and consequently increase Mϕs
subset in AT. In CC, high MCP-1 levels found in WSC might
be suggestive of a pre-cachexia stage, once increased gene
expression of CD68, IL-6 and IL-10 was already demonstrated
in such CC patients11. However, the relationship between
MCP-1-associated ATMϕs augment and the initial signals of
cachexia, as well as the importance of this process for the
development and progression of cachexia complications,
remains unclear.
Limitations of this study should be acknowledged. Our
investigation was carried out with relatively small study
groups. The Brazilian patients enrolled may not be represen-
tative of a typical cancer patient population from Europe or
North America and some differences concerning total fat
mass of patient in the cancer groups, and overweight and
obesity prevalence should be considered. Cachectic groups
showed values ranging from 9% to 31% of body weight loss
in the previous 6months and C-reactive protein ranging from
4.9 to 77μg/mL, indicating that we studied patients staging
between cachexia and refractory cachexia. Regarding the
WSC patients, some of them could be perhaps considered
pre-cachectic, once they showed values ranging from 3.2%
to 5.4% of body weight loss in the previous 6months
and C-reactive protein values ranging from 1.2 to 10.75μg/mL.
However, there was no difference when compared with
controls, and we have not attempted to adopt this staging
system to classify CC, due to the relatively small sample.
The current study was addressed to assess the effect of
cachexia and tumour per se but was not empowered to
detect differences between different tumour types. However,
the study was powered to detect the observed differences in
fibrosis and inflammation in scAT.
Conclusion
We report consistent modification consisting of fibrosis and
inflammatory cell presence in scAT induced by cachexia in
gastrointestinal cancer patients. The latter was characterized
by the presence of CLS composed of CD68 positive ATMϕs
surrounding adipocytes, and increased CD3 Ly, more evident
in the fibrotic areas. In addition, some of these changes were
already present in the cancer group, suggesting that AT dis-
ruption may occur at a precocious stage of cachexia, even be-
fore the detection of pre-cachexia clinical features. In this
particular, increased MCP-1 and CD68 gene expression in
scAT of cancer patients may indicate an important role of
these inflammatory mediators as early biomarkers of cancer.
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